Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ · Healthcare
Harmony Biosciences Holdings, Inc. EBITDA 2020–2025
Harmony Biosciences Holdings, Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Harmony Biosciences Holdings, Inc. ebitda for the quarter ending March 31, 2026 was 48.9 M, a 27.01% decrease year-over-year.
- Harmony Biosciences Holdings, Inc. ebitda for the twelve months ending March 31, 2026 was 237.0 M.
- Harmony Biosciences Holdings, Inc. annual ebitda for 2025 was 255.0 M, a 9.27% increase from 2024.
- Harmony Biosciences Holdings, Inc. annual ebitda for 2024 was 233.4 M, a 0.92% increase from 2023.
- Harmony Biosciences Holdings, Inc. annual ebitda for 2023 was 231.3 M, a 57.48% increase from 2022.
- Harmony Biosciences Holdings, Inc. annual ebitda for 2022 was 146.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Harmony Biosciences Holdings, Inc. EBITDA — FAQ
Harmony Biosciences Holdings, Inc. (HRMY) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see HRMY's ebitda history?
The chart and table above show Harmony Biosciences Holdings, Inc.'s ebitda by year and by quarter, including the growth rate.